Brilife
| Legal status | |
|---|---|
| Legal status |
|
| Pharmacokinetic data | |
| Protein binding | SARS-CoV-2 |
| Identifiers | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}} |
Brilife is the name of an israeli vaccine against the COVID-19 virus, developed by the Biological Institute in Ness Ziona.[1] Its development began in February 2020 and was completed in August 2020 with the start of human subject research of the vaccine in October of that year. The cabinet of Israel has invested 86 million ILS in its development.
The trade name of the vaccine means "Br for health (pronounced briut in Hebrew), il for the State of Israel and life."[2]
Human trials[edit]
In October 2020, the hospitals began recruiting the first 100 healthy individuals who will participate in the trial.
Phase 1 of the human trials is expected to occur at Hadassah University Medical Center in Jerusalem and Sheba Medical Center at Tel Hashomer.
If the safety of the product is proven in Phase 1, another 1,000 people are expected to be recruited to take part in a Phase 2 study. Phase 2 of the study is planned to take place sometime in the spring.
See Also[edit]
References[edit]
- ↑ "Israel to start human trials of COVID vaccine candidate 'Brilife' towards October-end". The Hindu. 2020-10-20. Retrieved 2020-10-20. Unknown parameter
|url-status=ignored (help) - ↑ Israel names its vaccine candidate: Brilife
.png){kind=small} | This article about the COVID-19 pandemic is a stub. You can help EverybodyWiki by expanding it. |
This article "Brilife" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Brilife. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
